Information Provided By: 
Fly News Breaks for March 30, 2016
ACAD, AXON
Mar 30, 2016 | 07:24 EDT
After an FDA panel recommended approval by a 12-2 vote of ACADIA's (ACAD) drug pimavanserin for the treatment of psychosis with Parkinson's disease, RBC Capital says that Axovant (AXON) has a positive read through from the vote. The firm says that Axovant's drug is also an oral 5HT2 inverse agonist and that AXON's drug has shown signs of having greater efficacy than ACADIA's drug. RBC keeps an Outperform rating on Axovant.
News For AXON;ACAD From the Last 2 Days
There are no results for your query AXON;ACAD
